[Business Wire] - ARIAD Pharmaceuticals, Inc. today announced long-term durability-of-response data from its Phase 1 trial of Iclusig® in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia .
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment